In particular, IL3-exosomes loaded with imatinib statistically reduced the tumor burden when compared with IL3-exosomes without imatinib, normal exosomes loaded with imatinib, and imatinib alone (p < 0.0005) in a mouse model [163]. Here, IL3 is linked to neoplasm.